An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Senstar Technologies announced its financial results for the fourth quarter and full year of 2023. The company will host a conference call to discuss its operational and financial highlights on April 1st, 2024.
Senstar Technologies ha annunciato i risultati finanziari del quarto trimestre e dell'intero anno 2023. L'azienda organizzerà una conferenza telefonica per discutere i punti salienti operativi e finanziari il 1° aprile 2024.
Senstar Technologies anunció sus resultados financieros para el cuarto trimestre y el año completo de 2023. La compañía realizará una llamada de conferencia para discutir los aspectos destacados operativos y financieros el 1 de abril de 2024.
센스타 테크놀로지스는 2023년 4분기 및 전체 연도의 재무 결과를 발표했습니다. 회사는 2024년 4월 1일에 운영 및 재무 하이라이트를 논의하기 위해 컨퍼런스 콜을 개최할 예정입니다.
Senstar Technologies a annoncé ses résultats financiers pour le quatrième trimestre et l'année entière de 2023. La société organisera une conférence téléphonique pour discuter des points forts opérationnels et financiers le 1er avril 2024.
Senstar Technologies gab seine Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2023 bekannt. Das Unternehmen wird am 1. April 2024 eine Telefonkonferenz abhalten, um die betrieblichen und finanziellen Höhepunkte zu besprechen.
Positive
None.
Negative
None.
ANN ARBOR, MI / ACCESSWIRE / March 20, 2024/ Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, will host a conference call and audio-only webcast on Monday, April 1st, 2024, at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its fourth quarter and full year ended December 31, 2023. A question-and-answer session will follow management's prepared remarks.
Event: Zomedica Corp. Q4 and Full Year 2023 Financial Results Conference Call
Date: Monday, April 1, 2024
Time: 4:30 p.m. Eastern Time
Live Call: +1-877-407-0789 (U.S. Toll-Free) or +1-201-689-8562 (International)
For interested individuals unable to join the conference call, a dial-in replay of the call will be available until Monday, April 15, 2024, at 11:59 AM ET and can be accessed by dialing +1-844-512-2921 (U.S. Toll-Free) or +1-412-317-6671 (International) and entering replay pin number: 13745341.
About Zomedica Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica's mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.zomedica.com.
zomedica (nyse american:zom) (tsx-v:zom) is a veterinary diagnostic and pharmaceutical and company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. zomedica’s product portfolio will include novel diagnostics and innovative therapeutics that emphasize patient health and practice health. with a team that includes clinical veterinary professionals, it is zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care.
